Product nameAnti-Thrombomodulin antibody
See all Thrombomodulin primary antibodies
DescriptionRabbit polyclonal to Thrombomodulin
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Monkey
Synthetic peptide within Human Thrombomodulin aa 500 to the C-terminus conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
(Peptide available as
- This antibody gave a positive signal in the following Human tissue lysates: Heart; Lung; Kidney; Placenta.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab94373 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 70 kDa (predicted molecular weight: 60 kDa).|
FunctionThrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.
Tissue specificityEndothelial cells are unique in synthesizing thrombomodulin.
Involvement in diseaseDefects in THBD are the cause of thrombophilia due to thrombomodulin defect (THR-THBD) [MIM:188040]. A hemostatic disorder characterized by a tendency to thrombosis.
Defects in THBD are a cause of susceptibility to hemolytic uremic syndrome atypical type 6 (AHUS6) [MIM:612926]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
Sequence similaritiesContains 1 C-type lectin domain.
Contains 6 EGF-like domains.
The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.
- Information by UniProt
- AHUS 6 antibody
- AHUS6 antibody
- BDCA 3 antibody
All lanes : Anti-Thrombomodulin antibody (ab94373) at 1 µg/ml
Lane 1 : Human heart tissue lysate - total protein (ab29431)
Lane 2 : Lung (Human) Tissue Lysate
Lane 3 : Human kidney tissue lysate - total protein (ab30203)
Lane 4 : Human placenta tissue lysate - total protein (ab29745)
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 60 kDa
Observed band size: 70 kDa why is the actual band size different from the predicted?
Additional bands at: 21 kDa, 32 kDa, 55 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 20 minutes
Thrombomodulin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. Abcam recommends using milk as the blocking agent. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.